Nature Nanotechnology, Published online: 23 July 2026; doi:10.1038/s41565-026-02194-1 A lipogel tailored with a differential and sustained release of combinatorial drugs can elicit tumour immunogenicity to counteract stemness-associated immunosuppression and augment immune-checkpoint-inhibitor-based immunotherapy.